Financial Gravity Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Financial Gravity Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2	Closed	-$263	–	1623
2024 Q1	$263	Sell	2 -5	-71%	-$612	﹤0.01%	919
2023 Q4	$982	Buy	+7	New	+$874	﹤0.01%	794
2021 Q3	$130K	Hold	8	–	–	0.06%	281
2021 Q2	$178K	Buy	+8	New	+$1.39K	0.06%	211
2020 Q4	$8K	Buy	+47	New	+$7K	0.01%	197
2019 Q4	$149K	Sell	520 -261	-33%	-$35.5K	0.1%	187
2019 Q3	$100K	Sell	781 -175	-18%	-$23.5K	0.09%	207
2019 Q2	$136K	Sell	956 -203	-18%	-$27.3K	0.11%	191
2019 Q1	$166K	Buy	+1,159	New	+$151K	0.13%	155
2018 Q3	$171K	Sell	1,114 -55	-5%	-$9.46K	0.18%	145
2018 Q2	$206K	Sell	1,169 -102	-8%	-$16.7K	0.19%	105
2018 Q1	$192K	Buy	+1,271	New	+$186K	0.2%	100

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Financial Gravity Asset Management's JAZZ Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 2 shares — an estimated $263 sold.

Financial Gravity Asset Management first reported a position in JAZZ in Q1 2018 and held it in 12 quarters. The position peaked at $206K in Q2 2018. 456 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Financial Gravity Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 2 Jazz Pharmaceuticals shares in Q2 2024, an estimated $263.
Financial Gravity Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 12 quarters.
Financial Gravity Asset Management's Jazz Pharmaceuticals position peaked at $206K in Q2 2018.
456 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.